A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML.

Trial Profile

A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Midostaurin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms MIDOKIT
  • Most Recent Events

    • 25 Jul 2018 Planned primary completion date changed from 1 May 2018 to 1 Jan 2020.
    • 25 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 11 Sep 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top